SPONSOR
Base Therapeutics (Shanghai) Co., Ltd.
Total Trials
2
Recruiting
2
Phases
EARLY_Phase 1
Clinical Trials by Base Therapeutics (Shanghai) Co., Ltd.
NCT06541405 EARLY_Phase 1
Recruiting
Safety and Efficacy of NK520 to Treat Pediatric Relapsed/Refractory Acute Myeloid Leukemia
Relapsed/Refractory Acute Myeloid Leukemia
NCT07561437 EARLY_Phase 1
Recruiting
NK521 in the Treatment of Malignant Ascites Associated With Advanced Solid Tumors
Advanced Solid Tumors
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology